Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 82

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 82
---
implified method” to estimate the expected term of its share-based awards.
The simplified method computes the expected term as the sum of the award’s vesting term plus the original contractual term divided
by two.

Recently Enacted Accounting Standards

For a description of recent accounting
standards, including the expected dates of adoption and estimated effects, if any, on our consolidated financial statements, see “Note
1: Recent Accounting Pronouncements” in the financial statements included elsewhere in this Annual Report.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

The Company is a smaller reporting company and is not
required to provide this information.

Item 8. Financial Statements and Supplementary
Data

63

Lunai Bioworks Inc. AND SUBSIDIARIES

Index to Consolidated Financial Statements 

Page 

Report of Independent Registered Public Accounting Firm (PCAOB ID:3627)
F-2

Consolidated Balance Sheets at June 30, 2025 and 2024
F-4

Consolidated Statements of Operations for the Years Ended June 30, 2025 and 2024
F-5

Consolidated Statements of Comprehensive Loss for the Years Ended June 30, 2025 and 2024
F-6

Consolidated Statement of Stockholders’ Equity (Deficit) for the Years Ended June 30, 2025 and 2024
F-7

Consolidated Statements of Cash Flows for the Years Ended June 30, 2025 and 2024
F-8

Notes to the Consolidated Financial Statements
F-9

F-1

REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of Lunai Bioworks, Inc. (fka:
Renovaro, Inc.):

Opinion
on the Financial Statements

We have audited the accompanying consolidated balance
sheets of Lunai Bioworks, Inc. (fka: Renovaro, Inc.) (“the Company”) as of June 30, 2025 and 2024, the related consolidated
statements of operations, comprehensive loss, stockholders’ equity(deficit), and cash flows for each of the years in the two-year
period ended June 30, 2025 and the related notes (collectively referred to as the “financial statements”). In our opinion,
the financial statements referred to above present fairly, in all material respects, the financial